Recent news on Visudyne

Accelerating decline foreseen for QLT's key Visudyne eye drug  -  Apr 26, 2007
Canada.com,..."In addition, although we believe Visudyne will ultimately play a role in combination therapy, we feel the (European) ruling further illustrates the uphill

QLT says CHMP to recommend deleting 'occult' indication of ...  -  Apr 25, 2007
Hemscott,The group said it is unclear what effect this decision will have on European Visudyne sales, in which QLT and Novartis AG are partners.

QLT's CEO says company is looking to sell its Atrigel business.  -  May 17, 2007
CBC News,VANCOUVER (CP) - Sales of its key drug Visudyne used to treat a form of blindness have bottomed out and started to climb in recent weeks as doctors use the

Eye drug shows signs of revival after downturn  -  May 18, 2007
Toronto Star,Sales of QLT Ltd.'s key drug Visudyne used to treat a form of blindness have bottomed out and started to rise recently as doctors use the eye drug in

QLT'S Shareholders Elect Philip Livingston to the Board of Directors  -  May 18, 2007
PharmaLive.com (press release),In addition, we utilize two unique technology platforms, photodynamic therapy and Atrigel(R), to create products such as Visudyne(R) and Eligard(R).

QLT sees decline in sale of main product  -  Apr 25, 2007
Vancouver Sun (subscription),QLT Inc. announced today that its lead product — the anti-blindness treatment Visudyne — has been turned down in Europe for use with an oppthalmologic

Committee for Medicinal Products for Human Use Post-authorisation ...  -  Apr 27, 2007
PharmaLive.com (press release),Human Use (CHMP) adopted a positive opinion** to recommend the variation to the terms of the marketing authorisation for the medicinal product Visudyne.

Lead QLT product suffers a setback in Europe  -  Apr 26, 2007
Vancouver Sun (subscription),QLT Inc. said Wednesday that its lead product, the anti-blindness treatment Visudyne, has been turned down in Europe to treat a specific eye condition.

Ranibizumab, PDT combination successfully treats neovascular AMD  -  May 11, 2007
OSN SuperSite (subscription),The trial randomly assigned 162 patients to undergo Visudyne (verteporfin, Novartis) PDT combined with either monthly 0.5 mg injections of Lucentis

Meeting Highlights From The Committee For Medicinal Products For ...  -  Apr 27, 2007
Medical News Today (press release),The CHMP recommended that the indication for Visudyne (verteporfin), from Novartis Europharm Ltd, in the treatment of occult subfoveal choroidal

QLT discloses European regulators set to delete one use of Visudyne  -  26 Apr 2007
Canada.com,VANCOUVER (CP) - Drug developer QLT Inc. (TSX:QLT) says the European Commission is set to delete the use of its key Visudyne product to treat a specific eye

Lead QLT product suffers a setback in Europe  -  26 Apr 2007
Vancouver Sun (subscription),QLT Inc. said Wednesday that its lead product, the anti-blindness treatment Visudyne, has been turned down in Europe to treat a specific eye condition.

Visudyne sales fading  -  Apr 24, 2007
Toronto Star,VANCOUVER–QLT Inc. said yesterday global sales of its Visudyne macular-degeneration drug in the first quarter were down 42.7 per cent from a year ago at

QLT's Global Visudyne Sales Drop 43 Pct in 1st Qtr  -  Apr 23, 2007
Reuters.uk,O: Quote, Profile , Research) anti-blindness treatment Visudyne fell 42.7 percent in the first quarter, the company said on Monday, citing figures from its

QLT 1Q Visudyne Sales Slump  -  Apr 23, 2007
Houston Chronicle,NEW YORK — Canadian biopharmaceutical company QLT Inc. said Monday global sales of its Visudyne product, which fights age-related macular degeneration,

QLT 1Q Visudyne Sales Slump  -  Apr 23, 2007
Forbes,Canadian biopharmaceutical company QLT Inc. said Monday global sales of its Visudyne product, which fights age-related macular degeneration, fell 43 percent

Business Browser  -  Apr 24, 2007
Edmonton Journal (subscription),QLT, which releases full results for the January-March period on Thursday, said Visudyne sales in the United States "appear to have stabilized in January

TORONTO (CP) — Some of the most active companies traded Monday at ...  -  Apr 24, 2007
ChronicleHerald.ca,Down 18 cents or 2.1 per cent to $8.38 on 88909 shares after it disclosed that global sales of its Visudyne macular-degeneration drug were down 42.7 per

Stocks seen rising on mergers, resources  -  Apr 23, 2007
Canada.com,...laser eye-surgery company QLT Inc. could see weakness after it said first-quarter global sales of its Visudyne product plumetted 42.7 percent over the

Markets heading upwards ahead of open  -  Apr 23, 2007
Toronto Star,QLT Inc. (TSX: QLT) disclosed that global sales of its Visudyne macular-degeneration drug were down 42.7 per cent in the first quarter from a year earlier

Market Report -- In Play (WIRES)  -  Apr 23, 2007
MSN MoneyQLT (QLTI) reports that Novartis AG (NVS) announced global sales of QLT's Visudyne product of $61.2 mln for the quarter ended March 31, 2007.

Corporate earnings and US durable goods data send stocks higher  -  Apr 25, 2007
CBC News,QLT Inc. (TSX:QLT) dipped two cents to $8.09 after it said the European Commission is set to delete the use of its key Visudyne product to treat occult

I can see clearly now: New vision at biopharma company QLT  -  Apr 2, 2007
CanadianBusiness.com,Up until 2005 the company's flagship drug, Visudyne, dominated the world market for treating age-related blindness. Global sales topped US$480 million in

Stocks take a breather after runup; Barclays buys ABN Amro for US ...  -  Apr 23, 2007
CBC News,QLT Inc. (TSX:QLT) was down eight cents to $8.48 after it disclosed that global sales of its Visudyne macular-degeneration drug were down 42.7 per cent in

Stocks flat, oil rises; Barclays makes US$91.2B offer for ABN Amro  -  Apr 23, 2007
Vancouver Sun (subscription),QLT Inc. (TSX:QLT) shares were down 15 cents to $8.41 after it disclosed that global sales of its Visudyne macular-degeneration drug were down 42.7 per cent

Toronto stocks seen rising on mergers, resources  -  Apr 23, 2007
Reuters Canada,TO: Quote) could see weakness after it said first-quarter global sales of its Visudyne product plumetted 42.7 percent over the same period last year.

Stocks off to weak start; Barclays offers US$91.2B for ABN Amro  -  Apr 23, 2007
Edmonton Journal (subscription),QLT Inc. (TSX:QLT) shares were up 11 cents to $8.67 after it disclosed that global sales of its Visudyne macular-degeneration drug were down 42.7 per cent

International indicators up slightly ahead of North American ...  -  Apr 23, 2007
Winnipeg Free Press,QLT Inc. (TSX:QLT) disclosed that global sales of its Visudyne macular-degeneration drug were down 42.7 per cent in the first quarter from a year earlier at

Repeated bevacizumab injections similarly effective to initial ...  -  Apr 11, 2007
OSN SuperSite (subscription),In 20% of cases, surgeons also performed Visudyne (verteporfin, Novartis/QLT) photodynamic therapy at the time of the initial intravitreal bevacizumab

Sirion Series B Raises $45M For Phase III Ophthalmic Bid  -  Apr 9, 2007
BioWorld Online,..."Right now, there really isn't anything out there treating dry AMD - it's like before Visudyne [verteporfin, QLT Inc.] there wasn't anybody treating wet AMD

Protox announces senior management changes  -  Mar 27, 2007
CNW Telbec (Communiqués de presse),...infrastructure to support late stage clinical trials and the explosive growth leading up to the approval and launch of the Visudyne ophthalmic drug.

LifeSciences BC Announces Recipients of the 2007 British Columbia ...  -  27 Mar 2007
CNW Telbec (Communiqués de presse),Dr. Dolphin is also the lead creator of Visudyne, the lead product for QLT Inc., which made the company British Columbia's first biotech success story,

QLT settles 2001 lawsuits over Visudyne  -  Mar 5, 2007
Toronto Star,VANCOUVER – QLT Inc. (TSX: QLT) has settled most of its patent lawsuits with Massachusetts Eye and Ear Infirmary related to a 2001 dispute over its Visudyne

QLT settles 2001 lawsuits with Massachusetts Eye and Ear Infirmary  -  Mar 5, 2007
940 News,QLT has seen sales of Visudyne fall in recent quarters since the approval of Genentech's Lucentis in the United States last year and off-label use of

Is QLT the Comeback Kid?  -  Feb 26, 2007
Motley FoolThat's where Canadian drugmaker QLT (Nasdaq: QLTI) found itself last year, with sales of its top drug Visudyne getting eaten up by the competition and its

Mass. allows claim by four delivery drivers to proceed  -  Mar 6, 2007
Boston Globe,Visudyne, made by QLT and sold by Novartis, treats macular degeneration, the leading cause of vision loss in people over 55. (Bloomberg)

PDT more effective for myopic CNV in patients 55 years and younger ...  -  Mar 8, 2007
OSN SuperSite (subscription),...but verteporfin [Visudyne, Novartis] PDT ... appears to be the most suitable treatment option for myopic eyes with juxtafoveal CNV attributable to its

QLT Settles MEEI Lawsuit With Respect to the '303 Patent  -  Mar 5, 2007
CNW Telbec (Communiqués de presse),Atrigel is a registered trademark of QLT USA, Inc. Visudyne is a registered trademark of Novartis AG. Eligard is a registered trademark of Sanofi-Synthelabo

QLT Settles MEEI Lawsuit With Respect to the '303 Patent  -  Mar 5, 2007
PharmaLive.com (press release),Visudyne is a registered trademark of Novartis AG. Eligard is a registered trademark of Sanofi-Synthelabo Inc. QLT Inc. is listed on The NASDAQ Stock Market

Panel looks at immediate future for AMD treatments  -  Mar 2, 2007
OSN SuperSite (subscription),The reduced fluence strategy used in the VIM (Visudyne in Minimally Classic) Study and currently used by many clinicians involves decreasing the energy

QLT sees continuing decline in sales of main drug  -  Feb 22, 2007
CBC News,Revenue from QLT Inc.'s main product, the drug Visudyne, fell almost 31 per cent in 2006, the company said Thursday. And QLT is expecting further drops as

QLT expects Visudyne sales to fall in 2007, Eligard sales at US ...  -  Feb 22, 2007
Canada.com,In its outlook for 2007, the company said it expects sales of the Visudyne eye treatment to decline due to increased competition, but it did not provide

UPDATE 1-QLT sees Visudyne sales slipping in 2007 and beyond  -  Feb 22, 2007
ReutersTO: Quote, Profile , Research) said on Thursday it sees worldwide sales of Visudyne, its anti-blindness treatment, slipping in 2007 and 2008 due mainly to

UPDATE 2-QLT hit by weak Visudyne sales, pain seen lingering  -  Feb 22, 2007
Reuters...related to litigation at its US subsidiary and declining sales from its Visudyne anti-blindness treatment, which it said would linger for some time.

QLT Announces 2006 Results  -  Feb 22, 2007
PharmaLive.com (press release),As previously announced, Visudyne(R) sales for the fourth quarter were $76.5 million, a decrease of 28.7% over sales in the fourth quarter of 2005.

Market Report -- In Play (QLTI)  -  Feb 22, 2007
MSN Money..."In 2007, our primary objectives are to develop a robust ocular pipeline and stabilize Visudyne sales. Visudyne sales will continue to decline this year

QLT results hit by litigation charge  -  Feb 22, 2007
Reuters Canada,The company said fourth-quarter sales of its key anti-blindness treatment Visudyne were $76.5 million, down 28.7 percent from the same time in 2005.

QLT eye treatment comes back into focus  -  Feb 14, 2007
Globe and Mail,Heading the woeful list is imploding sales of its flagship Visudyne drug for macular degeneration and an utter guessing game where those sales will bottom

Genentech warns on blindness treatment  -  Jan 27, 2007
Los Angeles Times,The warning may create an opportunity for a rival drug, Visudyne from QLT Inc. Visudyne sales fell 29% in the fourth quarter.

Tolmar in sale-leaseback deal to snap up QLT USA  -  Feb 6, 2007
In-PharmaTechnologist.com,In October QLT was forced to drop its forecast annual sales range for Visudyne from $370m-$385m to $340m-$355m in the face of this new challenge,

3 Canadian scientists named for Herzberg award  -  Feb 7, 2007
CBC News,...be increased to $1 million over the next five years. Last year's winner was David Dolphin, the lead creator of Visudyne, a widely used anti-blindness drug.

New study reveals higher risk with Genentech drug  -  Jan 27, 2007
San Francisco Chronicle,The Lucentis data may open marketing opportunities for manufacturers of the competing drugs Visudyne, made by QLT Inc., and OSI Pharmaceuticals' Macugen.

QLT narrows losses  -  Feb 22, 2007
Toronto Star,That was on revenues of $175.1 million, down 23.8 per cent from $229.8 million as sales of its key eye treatment Visudyne continued to fall faster than its

QLT USA signs agreement with TAP to settle United States patent ...  -  Feb 9, 2007
CNW Telbec (Communiqués de presse),Atrigel is a registered trademark of QLT USA, Inc. Visudyne is a registered trademark of Novartis AG. Eligard is a registered trademark of Sanofi-Synthelabo

QLT USA signs agreement with TAP to settle United States patent ...  -  Feb 9, 2007
PharmaLive.com (press release),Visudyne is a registered trademark of Novartis AG. Eligard is a registered trademark of Sanofi-Synthelabo Inc. QLT Inc. is listed on The NASDAQ Stock Market

QLT Pays Up  -  Feb 13, 2007
Motley FoolQLT is not my favorite drug stock, and with Genentech's (NYSE: DNA) Lucentis gobbling up much of QLT's Visudyne market share as a treatment for

QLT shares trade lower after TAP patent lawsuit settlement last week  -  Feb 12, 2007
Canada.com,The settlement comes as QLT has struggled with falling sales of Visudyne, its main source of revenue, in the wake of new competition for age-related macular

Drug company QLT says Visudyne sales for Q4 fall 28.7 per cent  -  18 Jan 2007
CBC News,QLT's partner Novartis AG reported global Visudyne sales of about US$76.5 million for the quarter and US$353.8 million for the year ended Dec. 31.

Sección internacional  -  18 Jan 2007
Bolsamania.com,...(PRN) - QLT announces Visudyne(R) sales for fourth quarter and fiscal year 2006 ... [+]. (PRN) - Bull: Impact of the Sale of Italian Subsidiary to Eunics .

Novartis Strategic Healthcare Portfolio Drives Sustained Strong ...  -  18 Jan 2007
PharmaLive.com (press release),Visudyne (USD 354 million, -27% lc), a treatment for the eye disease "wet" age-related macular degeneration, reported a sharp decline in net sales linked to

QLT USA Receives Final Payment for Generic Dermatology and ...  -  Jan 4, 2007
PharmaLive.com (press release),Visudyne is a registered trademark of Novartis AG. Eligard is a registered trademark of Sanofi-Synthelabo Inc. QLT Inc. is listed on The NASDAQ Stock Market

QLT USA receives final payment for generic dermatology and ...  -  Jan 3, 2007
CNW Telbec (Communiqués de presse),Atrigel is a registered trademark of QLT USA, Inc. Visudyne is a registered trademark of Novartis AG. Eligard is a registered trademark of Sanofi-Synthelabo

QLT Inc. sells US generic dermatology and manufacturing business ...  -  Dec 22, 2006
Canada.com,QLT is best known for its Visudyne eye treatment for age-related macular degeneration, however the company has begun to see increasing competition for the

Eye on Genentech's Lucentis  -  Jan 10, 2007
TheStreet.comUnlike its competitors -- Visudyne sold by Novartis (NVS - commentary - Cramer's Take) and Macugen from OSI Pharmaceuticals (OSIP - commentary - Cramer's

QLT Inc. sells US generic dermatology and manufacturing business ...  -  Dec 22, 2006
Canada.com,QLT is best known for its Visudyne eye treatment for age-related macular degeneration, however the company has begun to see increasing competition for the

QLT announces divestment of QLT USA, Inc.'s generic dermatology ...  -  Dec 22, 2006
CNW Telbec (Communiqués de presse),Atrigel is a registered trademark of QLT USA, Inc. Visudyne is a registered trademark of Novartis AG. Eligard is a registered trademark of Sanofi-Synthelabo

QLT Announces Divestment of QLT USA, Inc.'s Generic Dermatology ...  -  Dec 22, 2006
PharmaLive.com (press release),Visudyne is a registered trademark of Novartis AG. Eligard is a registered trademark of Sanofi-Synthelabo Inc. QLT Inc. is listed on The NASDAQ Stock Market

QLT names Bruce Carter to board  -  Nov 29, 2006
BusinessWeekJulia has played a significant role in the success of QLT, in particular with respect to the successful development of Visudyne," said Boyd Clarke,

Advances in the Treatment of Age-Related Macular Degeneration  -  Dec 18, 2006
Medscape (subscription)Verteporfin (Visudyne) and pegaptanib (Macugen). Program and abstracts of the 2006 Joint Meeting of the American Academy of Ophthalmology and Asia Pacific

New hope for eye patients  -  Dec 11, 2006
Hagerstown Morning Herald,Then in 2000 a photodynamic therapy was approved by the FDA that involved injecting Visudyne into the arm. A cold laser light directed into the eye

On Healing  -  Dec 6, 2006
Nipawin Journal,A common drug used to help stabilize vision in wet AMD patients is Visudyne (which DeLance has taken). This drug, injected intravenously, is absorbed by the

Eligard® Six-Month Formulation Approved In Germany  -  Dec 1, 2006
PipelineReview.com (press release),...drug therapies with our two unique technology platforms, photodynamic therapy and Atrigel®, to create products such as Visudyne® and Eligard®.

Simple Treatment For Age-Related Macular Degeneration  24 Sep 2006
AMD. These are Lucentis, Macugen and Visudyne. ... improvement. Only one treatment for wet AMD - Visudyne - is available on the NHS. ... -Medical News Today

Analysis: Stem cells prevent vision loss  Sep 21, 2006
In the meantime, the macular degeneration field will be dominated by VEGF-inhibitors, with Genentech's Lucentis replacing Novartis' Visudyne as the leading ... -United Press International

Those Buybacks at QLT  Sep 12, 2006
...revenues declined 20% year over year to $48 million primarily because revenues for the company's leading drug for macular degeneration, Visudyne, were down 29 ... -Motley Fool

Private equity pursues takeout of QLT  Aug 28, 2006
...pressure on the company to implement the Dutch auction as a way of returning cash to shareholders in the face of declining sales of its one big drug, Visudyne. ... -Globe and Mail

The drug works but you can't have it  Sep 3, 2006
There is one treatment for wet AMD; Visudyne, licensed and approved for use in the NHS by the National Institute for Health and Clinical Excellence (Nice). ... -Times Online

QLT Announces Final Results of Tender Offer  Sep 14, 2006
...of innovative drug therapies with our two unique technology platforms, photodynamic therapy and Atrigel®, to create products such as Visudyne® and Eligard®. ... -Yahoo! News

QLT Announces Preliminary Results of Tender Offer  Sep 11, 2006
...of innovative drug therapies with our two unique technology platforms, photodynamic therapy and Atrigel(R), to create products such as Visudyne(R) and Eligard(R ... -PharmaLive.com

International Approvals: Azilect and Lucentis  Sep 11, 2006
...to an average 11.3-letter gain from baseline at 1 year compared with a loss of 9.5 letters in those given verteporfin photodynamic therapy (Visudyne, QLT, Inc ... -Medscape (subscription)

Private equity mulls hostile offer for QLT as board pursues ...  Aug 29, 2006
...to slide.". Shares of QLT have struggled as it has faced increasing competition for its main source of revenue Visudyne. The company ... -CBC News

QLT to pursue repurchase plan despite buyout talk  Aug 29, 2006
QLT launched the buyback plan in late July to prop up its flagging stock price hit by weak sales of its key ocular drug Visudyne and disappointing earnings. ... -Reuters Canada

Eligard(R) six-month formulation approved in Germany  -  12 Dec 2006
Drug Newswire (press release),Visudyne is a registered trademark of Novartis AG. Eligard is a registered trademark of Sanofi-Synthelabo Inc. QLT Inc. is listed on The Nasdaq Stock Market

Dr. Bruce Carter joins QLT's board of directors  -  Nov 29, 2006
CNW Telbec (Communiqués de presse),Atrigel is a registered trademark of QLT USA, Inc. Visudyne is a registered trademark of Novartis AG. Eligard is a registered trademark of Sanofi-Synthelabo

QLT names Bruce Carter to board  -  Nov 29, 2006
BusinessWeekJulia has played a significant role in the success of QLT, in particular with respect to the successful development of Visudyne," said Boyd Clarke,

New hope for eye patients  -  Dec 11, 2006
Hagerstown Morning Herald,Then in 2000 a photodynamic therapy was approved by the FDA that involved injecting Visudyne into the arm. A cold laser light directed into the eye

On Healing  -  Dec 6, 2006
Nipawin Journal,A common drug used to help stabilize vision in wet AMD patients is Visudyne (which DeLance has taken). This drug, injected intravenously, is absorbed by the

Eligard® Six-Month Formulation Approved In Germany  -  Dec 1, 2006
PipelineReview.com (press release),...drug therapies with our two unique technology platforms, photodynamic therapy and Atrigel®, to create products such as Visudyne® and Eligard®.

The eyes have it  -  Nov 26, 2006
Toronto Sun,One is a photo-dynamic therapy called Visudyne in which a drug is injected into the bloodstream and is activated in the eye by a non-heat laser -- thus

Intradigm Announces Significant Enhancements of the Company ...  -  Nov 21, 2006
Genetic Engineering News (press release),...in the approval and marketing of seven different new chemical entities in oncology and other therapeutic areas including Arimidex(R), and Visudyne(R).

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional